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Minimal residual disease (MRD) quantiﬁcation is an important predictor of outcome after treatment for acute
lymphoblastic leukemia (ALL). Bone marrow ALL burden  104 after induction predicts subsequent relapse.
Likewise, MRD  104 in bone marrow before initiation of conditioning for allogeneic (allo) hematopoietic
cell transplantation (HCT) predicts transplantation failure. Current methods for MRD quantiﬁcation in ALL are
not sufﬁciently sensitive for use with peripheral blood specimens and have not been broadly implemented in
the management of adults with ALL. Consensus-primed immunoglobulin (Ig), T cell receptor (TCR) ampliﬁ-
cation and high-throughput sequencing (HTS) permit use of a standardized algorithm for all patients and can
detect leukemia at 106 or lower. We applied the LymphoSIGHT HTS platform (Sequenta Inc., South San
Francisco, CA) to quantiﬁcation of MRD in 237 samples from 29 adult B cell ALL patients before and after allo-
HCT. Using primers for the IGH-VDJ, IGH-DJ, IGK, TCRB, TCRD, and TCRG loci, MRD could be quantiﬁed in 93%
of patients. Leukemia-associated clonotypes at these loci were identiﬁed in 52%, 28%, 10%, 35%, 28%, and 41%
of patients, respectively. MRD  104 before HCT conditioning predicted post-HCT relapse (hazard ratio [HR],
7.7; 95% conﬁdence interval [CI], 2.0 to 30; P ¼ .003). In post-HCT blood samples, MRD 106 had 100%
positive predictive value for relapse with median lead time of 89 days (HR, 14; 95% CI, 4.7 to 44, P < .0001).
The use of HTS-based MRD quantiﬁcation in adults with ALL offers a standardized approach with sufﬁcient
sensitivity to quantify leukemia MRD in peripheral blood. Use of this approach may identify a window for
clinical intervention before overt relapse.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Tremendous progress has been made in the management
of acute lymphoblastic leukemia (ALL) in children; in part,
through the wide use of minimal residual disease (MRD)
monitoring in bone marrow (BM) aspirates to guide thera-
peutic intensiﬁcation before and after allogeneic (allo) he-
matopoietic cell transplantation (HCT) [1-7]. Nonetheless,
regional differences in standardization and the high costs ofedgments on page 1312.
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14.04.018MRD testing have limited its use in the management of adult
ALL. Similar to the signiﬁcance of MRD positivity after in-
duction therapy for pediatric ALL, MRD evaluation in adults
with ALL has been shown to be useful for predicting clinical
outcomes [8,9]. A broadly applicable MRD quantiﬁcation
method that addresses the limitations of currently available
MRD technologies has the potential to signiﬁcantly improve
the management of ALL in adults.
At present, 2 prevailing technologies are available for
quantiﬁcation of MRD in ALL: real-time quantitative poly-
merase chain reaction (RQ-PCR) and multiparametric ﬂow
cytometry (MPFC). MRD quantiﬁcation in BM specimens
from patients with ALL using immunoglobulin (Ig) and T cell
receptor (TCR) RQ-PCR with allele-speciﬁc primers andTransplantation.
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dardization in Europe via the EuroMRD consortium [10].
Unfortunately, this methodology has not become a standard
of practice in the United States and elsewhere because of the
signiﬁcant expense and expertise required to develop such
patient-speciﬁc genetic assays.
Remission bone marrow specimens may alternatively be
assessed by MPFC for aberrant blast immunophenotypes
using standardized antibody panels [11]; however, this
method has decreased sensitivity in comparison with mo-
lecular disease quantiﬁcation, requires assessment of fresh
tissue for best results, and may be subject to interlaboratory
variability due to differing population gating strategies dur-
ing ﬂow cytometric analyses.
Although PCR-based and ﬂow-based methods both have
merits, molecular quantiﬁcation of clonal Ig/TCR gene rear-
rangements in leukemic blasts has been repeatedly demon-
strated to provide the most sensitive and speciﬁc MRD
quantiﬁcation with a detection limit of roughly 105 (ie, 1
leukemic cell in 100,000 leukocytes). Post-therapy MRD
burden104 in BM aspirates, using either RQ-PCR or MPFC,
has been demonstrated to be a more powerful prognostic
marker for subsequent relapse than those typically used,
including age, WBC count at diagnosis, and cytogenetic al-
terations [12,13].
To date, the potential advantages of higher sensitivity
MRD quantiﬁcation have remained somewhat theoretical.
Some studies have shown, however, that patients who are
MRD positive by a PCR-based method but MRD negative
by MPFC are at increased risk for relapse compared with
patients who are MRD negative with both techniques [14-
16]. This suggests higher sensitivity may indeed be clini-
cally useful. Additionally, a largely unscrutinized potential
beneﬁt of higher sensitivity is the possibility of meaningful
detection of MRD in peripheral blood (PB) instead of BM
[17]. In the present study, we applied a next-generation
sequencingebased MRD assay, termed the LymphoSIGHT
platform (Sequenta) [18], which has a quantitative range to
105 andmay have sensitivity to below 106 with adequately
cellular specimens, to quantify ALL MRD in BM or PB samples
before and after allo-HCT.
Another challenge inALLMRDquantiﬁcationaddressedby
the high-throughput sequencing (HTS) method we studied is
identifying clonal rearrangements inmultiple Ig/TCR genes in
ALL. Most B and T cell ALL patients exhibit clonal rearrange-
ments of 1 ormore immunoglobulin (heavychain, IGH; kappa
or lambda light chain, IGK/IGL) or T cell receptor (beta, TCRB;
delta, TCRD; gamma, TCRG) genes. Such gene rearrangements
represent a genetic “barcode” within every lymphocyte that
permits quantiﬁcation of speciﬁc clonal populations and this
phenomenon is the principle upon which RQ-PCR methods
for MRD quantiﬁcation are based. Fifty to 75% of B cell ALL (B-
ALL) patients have a disease-associated IGH-VDJ clonotype
detectable [19-21]. Roughly 10% to 30% of B-ALL isolates
lacking a stable IGH-VDJ rearrangement have a stable and
unique IGH-DJ partial rearrangement detectable [20,22,23].
Other immunoreceptor loci may also undergo rearrangement
inprecursor BandT lymphoblasts. TCRB rearrangementshave
been detected in up to 35% of patients with B-ALL and more
than 75% of patients with T cell ALL (T-ALL) [24,25], whereas
the TCRDandTCRG loci are clonally rearranged in a signiﬁcant
minority of B-ALL isolates [20].
In this study, we applied the LymphoSIGHT
method (Sequenta) to assess clonality at the IGH locus
(complete IGH-VDJ rearrangements and partial IGH-DJrearrangements), the IGK locus, and the TCRB, TCRD, and
TCRG loci, in diagnostic specimens from adult patients with
B-ALL. The leukemia-associated clonotypes were then
quantiﬁed in cryopreserved pre- and post-transplantation PB
and BM samples and correlations between disease burden
and clinical outcomes were evaluated.
PATIENTS AND METHODS
Study Subjects
Forty-two ALL patients who underwent allo-HCT were eligible for this
retrospective study based on the availability of diagnostic samples believed
to contain leukemic cells and a minimum of 3 years post-HCT follow-up.
Cryopreserved RNA isolates from diagnostic specimens in 13 patients were
found to have unsuitable quality for comprehensive clone identiﬁcation and
no DNA or tissue samples were available; thus, 29 patients with genomic
DNA samples taken at diagnosis or relapse were studied for immunor-
eceptor clonality and pre- and post-HCT molecular MRD. Patients provided
informed consent to tissue sample archival and this study was approved by
the Stanford University School of Medicine institutional review board.
Conditioning Regimens and Graft-Versus-Host Disease Prophylaxis
Patients underwent allo-HCT at Stanford University between May 2004
to March 2010. Pretransplantation conditioning regimens were myeloa-
blative preparations with 1200 to 1320cGy total body irradiation (22 pa-
tients; 11 with cyclophosphamide, 8 with etoposide, and 3 with both) or
chemotherapy (2 patients), or nonmyeloablative (NMA) preparation with
total lymphoid irradiation and antithymocyte globulin (5 patients). Grafts
were comprised of BM (5 patients) or granulocyte colonyestimulating fac-
toremobilized peripheral blood apheresis products (24 patients), and origi-
nated frommatched sibling donors (17 patients), matched unrelated donors
(10 patients), or haploidentical donors (2 patients). All patients undergoing
myeloablative preparation received standard immune prophylaxis with
methotrexate and a calcineurin inhibitor. Recipients of NMA received pro-
phylactic therapy with mycophenolate mofetil and a calcineurin inhibitor.
Tissue Sampling and MRD Quantiﬁcation
PB mononuclear cells (PBMC) from 10 mL of whole blood or 5 mL BM
mononuclear cell (BMMC) samples from marrow aspirates were collected
and cryopreserved in liquid nitrogen vapor at diagnosis, prospectively
planned post-transplantation time points, and at relapse. Post-HCT samples
were retrieved from storage, thawed, washed, and genomic DNA was iso-
lated from cells using a DNeasy kit (Qiagen, Valencia, CA) according to
manufacturer’s instructions.
Genomic DNA samples were then processed as described elsewhere
[18]. Brieﬂy, using Sequenta’s LymphoSIGHT platform, we ampliﬁed and
sequenced rearranged immunoreceptor loci from genomic DNA samples
using V and J segment consensus primers for each gene (IGH, IGK, TCRB,
TCRD, and TCRG) and, in some cases, D segment primers for incomplete IGH-
DJ rearrangements.
Sequences were analyzed using standardized algorithms for clonotype
determination. Leukemia-speciﬁc clonotypes were identiﬁed for each pa-
tient, based on their high prevalence in a blood or marrow sample at a time
of high disease burden. MRD levels were then determined in serial samples
of PBMC or BMMC and quantiﬁed using spiked-in reference sequences in the
reaction mixture to permit control for oversequencing, thus enabling
reporting of absolute clonotype frequency [18].
Deﬁnition of Outcomes
We evaluated time to events, deﬁned as the interval between graft
infusion (day 0) and MRD positivity or clinical relapse as determined by
standard diagnostic criteria. Disease-free survivalwas deﬁned as the interval
between graft infusion and clinical relapse, the latter being deﬁned by the
recurrence of excess blasts exhibiting an immunophenotype congruent with
the original diagnosis. Overall survival was deﬁned as the interval between
graft infusion and death from any cause.
Statistical Analyses
Disease-free survival and overall survival were estimated by the Kaplan-
Meier method. GraphPad Prism (GraphPad Software, La Jolla, CA) was used
to generate Kaplan-Meier curves and other ﬁgures after primary analysis in
R or Spotﬁre (Tibco, Somerville, MA).
RESULTS
Patient and Sample Characteristics
Forty-two ALL patients who underwent allo-HCT were
considered for this retrospective study. The LymphoSIGHT
Table 1
Patient Features
Characteristic n (%)
Total patients 29
Recipient gender, M/F 16/13
Age, median (range), yr 34 (16-67)
Subtype
B-ALL 29 (100)
Risk feature
Phþ 11 (38)
Status at HCT
CR1 12 (41)
CR2 9 (31)
CR3 2 (6.9)
Relapse/refractory 6 (21)
Regimen
Ablative 24 (83)
Nonmyeloablative 5 (17)
Graft
PBSC 24 (83)
BM 5 (17)
Donor
Matched sibling 17 (59)
Matched unrelated 10 (34)
Haploidentical 2 (6)
Status at last f/u
Alive 7 (24)
Dead 22 (76)
DFS, median (range), days 252 (74-3110)
OS, median (range), days 572 (85-3110)
M indicates male; f, female; B-ALL, B cell acute lymphoblastic leukemia;
Phþ, Philadelphia chromosome positive; HCT, hematopoietic cell trans-
plantation; CR, complete remission; PBSC, peripheral blood stem cells; BM,
bonemarrow; f/u, follow-up; DFS, disease-free survival; OS, overall survival.
Table 2
Clonotype Identiﬁcation in Diagnostic Samples
IGH-VDJ IGH-DJ IGK TCRB TCRD TCRG
IGH-VDJ 15 3 3 6 7 7
IGH-DJ 3 8 1 0 2 2
IGK 3 1 3 3 3 2
TCRB 6 0 3 10 6 5
TCRD 7 2 3 6 8 4
TCRG 7 2 2 5 4 12
IGH indicates heavy chain immunoglobulin; IGK, kappa light chain; TCRB,
T cell receptor beta; TCRD, T cell receptor delta; TCRG, T cell receptor
gamma.
In this 29-patient cohort, 15 (52%) had identiﬁable IGH-VDJ clonotypes.
Twelve of 14 (86%) who did not have an IGH-VDJ clonotype were found to
have a clonotype at 1 or more other loci as indicated. Coincident rear-
rangements are shows in columns and bold numbers signify the total fre-
quency at which each locus was clonotyped in this series of patients.
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Figure 1. Frequency of disease clonotype in diagnostic samples. At least 1
immunoreceptor clonotype suitable for use in MRD quantiﬁcation was iden-
tiﬁed in 93% of patients with ALL. The number of leukemia-associated
immunoreceptor locus rearrangements per patient are shown in (A). For
each of the immunoreceptors tested, the frequency of dominant clonotypes in
diagnostic specimens is shown in (B). Clonotype frequency greater than 5%
(dotted line) was required to identify disease-associated immunoreceptor
rearrangements.
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the availability of a diagnostic specimen with adequate dis-
ease burden for identiﬁcation of the Ig/TCR clonotypes spe-
ciﬁc to the leukemia cell population. For 13 patients, only
RNA samples isolated from trizol lysates obtained at diag-
nosis were available. These samples were, unfortunately,
degraded to an unacceptable quality and were not suitable
for this study. Thus, we limited this survey to 29 patients
with B-ALL based on availability of genomic DNA from a
diagnostic sample (PB or BM) with adequate disease
burden for identiﬁcation of the leukemia-associated immu-
noreceptor clonotype(s) to be quantiﬁed in pre- and post-
HCT samples (Table 1). Eleven patients (38%) had a t(9;22)
translocation consistent with Philadelphia chromosome
positive disease. Twelve patients (41%) were in ﬁrst complete
remission (CR), 9 (31%) in second CR, 2 (7%) in third CR, and 6
(21%) had relapsed/refractory disease at the time of condi-
tioning. Twenty-four patients (83%) underwent myeloa-
blative preparation and 5 (17%) received NMA. In total, 237
samples (176 PB and 61 BM) were analyzed by the Lym-
phoSIGHT platform (Sequenta), including 29 leukemia-
bearing samples and 208 pre- and post-HCT samples for
MRD quantiﬁcation.
Ig and TCR Locus Rearrangements in ALL
A clonal IGH sequence with a complete VDJ rearrange-
ment was identiﬁed in 15 of 29 (52%) patients, whereas
partial IGH-DJ rearrangements were observed in 8 (28%)
patients. Other immunoreceptor loci exhibiting clonality
included IGK in 3 (10%), TCRB in 10 (35%), TCRD in 8 (28%),
and TCRG in 12 (41%) (Table 2). Among patients who did not
have a detectable IGH clonotype, 12 of 14 (86%) had clonal
sequences at 1 or more other loci, including partial IGH-DJ
rearrangements (5 of 14; 38%), TCRB (4; 31%), TCRD (2;15%), or TCRG (5; 38%). Leukemia-associated IGK clonotypes
were identiﬁed only in leukemia isolates also possessing an
IGH clonotype. In total, 27 of 29 (93%) patients had 1 or more
clonal Ig/TCR sequences suitable for MRD quantiﬁcation us-
ing LymphoSIGHT (Sequenta). Thirty-eight percent had just 1
rearranged locus suitable for MRD quantiﬁcation, whereas
21% had 2, 21% had 3, 3.4% had 4, and 6.9% had 5 (Figure 1A).
When clonal rearrangements of speciﬁc loci were iden-
tiﬁed in diagnostic specimens, they comprised 58  18% of
the IGH-VDJ repertoire, 63  40% of the IGH-DJ repertoire,
71  16% of the IGK repertoire, 47  22% of the TCRB reper-
toire, 55  24% of the TCRD repertoire, and 56  23% of the
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quency cut-off required for identiﬁcation of leukemia-
associated clonotypes (Figure 1B).
Blood versus BM MRD Quantiﬁcation
Among 37 contemporaneous PB and BM samples evalu-
ated by the LymphoSIGHT platform (Sequenta), 18 (49%)
were concordantly MRD negative. Four (11%) were MRD
positive in BM but negative in PB, and the median disease
burden in these samples was 5.5  106 (range, 4.5  106 to
1.7  105). Twelve (32%) exhibited higher MRD in BM (.18;
range, 2.8  103 to 1.0) versus PB (9.6  103; range
1.0  105 to .49) and 3 (10%) were equivalent or slightly
lower in BM (2.6  103; range 6  106 to 4.7  103) than
PB (7.0 103; range 1.4105 to 7.8 103), representing a
median 8.4-fold higher (range, .3 to 115-fold) disease burden
in BM (Figure 2A). Additional PB samples with low disease
burden (106 range) were present in this study, but did not
have concurrent marrow samples for this comparison.
Among the 134 PB specimens without a contemporaneous
BM specimen, disease burden was quantiﬁable in 63 with a
disease burden ranging 2.8  107 to 1.0 (Figure 2B).
Prognostic Value of Pre- and Post-HCT MRD
Quantiﬁcation in Blood and BM
The leukemia-speciﬁc clonotypes identiﬁed in diagnostic
materials were used to screen the Ig/TCR repertoires of pre-10
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Figure 2. Comparison of molecular MRD sensitivity in bone marrow aspirates
and peripheral blood. In 37 paired bone marrow (BM) aspirate and peripheral
blood (PB) samples, MRD quantiﬁcation was concordantly negative (0) in 18
(49%). MRD quantiﬁcation was discordantly positive in BM while negative in
PB in 4 (11%), and the median disease burden in these BM samples was
5.5  106 (range, 4.5  106 to 1.7  105). When MRD was detected in both
sample sources, disease burden was higher (median, 8.4-fold) in BM than PB,
as shown in (A). MRD quantiﬁcation in all samples in this study is demon-
strated in (B).and post-HCT PBMC samples for MRD. When IGH-VDJ was
clonal, this immunoreceptor was used for MRD quantiﬁca-
tion, and other Ig/TCR loci, even if found to be rearranged on
initial screening, were not queried in remission samples. In
patients not possessing a leukemia-speciﬁc IGH-VDJ clono-
type, MRD samples were screened for the clonotype exhib-
iting the highest result from the diagnostic sample.
Of the 27 patients with leukemia clonotypes available to
quantify forMRDassessment, 22hada blood sample available
within 30 days before initiation of transplantation condi-
tioning. Nine patients (41%) had noMRD detected at the 106
detection threshold of the LymphoSIGHT platform
(Sequenta). Two patients (9.1%) had disease burden in the
106 range, 4 patients (18.2%) had disease burden in the 105
range, and MRD was  104 in 7 patients (32%). Disease
burden  104 within 30 days before HCT was signiﬁcantly
associated with post-HCT relapse (hazard ratio [HR]. 7.7; 95%
conﬁdence interval [CI] 2.0 to 30; P ¼ .003) (Figure 3A). The
presence of MRD <104 was not a signiﬁcant predictor of0 12 24 36 48 60 72 84 96
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Figure 3. Disease-free survival impaired by pre- or post-transplantation MRD.
ALL disease burden  104 during the 30 days before transplantation strongly
predicts likelihood of disease-free survival after transplantation (HR, 7.7; 95%
CI, 2.0 to 30; P ¼ .003) is shown in (A). (B) Shows MRD positivity (106) at
any time through day þ100 after transplantation predicts subsequent relapse
(HR, 14; 95% CI, 4.7 to 44; P < .0001).
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withMRDbetween 104 and 106was limited in this data set.
Samples collected before day 100 post-HCT in 24 patients
were evaluated for MRD. Twelve patients (50%) achieved or
maintained molecular remission (<106) within the ﬁrst
90 days after HCT and 12 (50%) did not. In the MRD-negative
group, 6 of 12 patients (50%) ultimately relapsed, with a
median time to clinical progression of 320 days after HCT
(range, 77 to 889), whereas 12 of 12 patients (100%) in the
MRD-positive group (3 with  104 MRD, 5 between 104
and 105, and 4 between 105 and 106) relapsed with a
median time to clinical progression of 162 days after HCT
(range, 77 to 304) (HR, 14; 95% CI, 4.7 to 44; P < .0001)
(Figure 3B).Time Interval from Molecular Failure to Clinical Events
Of the 8 patients who maintained MRD negativity
(<106) in PB after HCT, 6 (75%) remain alive at a median
1853 days (range, 1651 to 2732 days), and 2 (25%) died in
remission from complications of chronic graft-versus-host
disease (at 1047 and 2675 days after HCT). One patient was
MRD negative at 34 days after HCT and did not have subse-
quent samples stored before relapsing 176 days after HCT. All
17 patients with MRD  106 detected at any time after HCT
relapsed and all died (median survival, 359 days; range, 85 to
1991 days) (Figure 4A). The lead time between molecular
disease detection by Ig/TCR-HTS and clinical relapse was a
median of 89 days (range, 0 to 207 days) (Figure 4B).0 12 24 36 48 60 72 84 96 10
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Figure 4. Overall survival and time to event analysis. (A) Patients with
persistent MRD negativity experienced signiﬁcantly higher overall survival
after hematopoietic cell transplantation (HCT) than patients with transient
MRD negativity and failure to achieve MRD negativity (P < .0001). (B) shows
the Kaplan-Meier estimate of time from molecular progression to clinical
relapse and death for patients who relapsed. The median time from molecular
progression to relapse was 89 days.DISCUSSION
MRD quantiﬁcation has been successfully incorporated
into the majority of pediatric treatment regimens through
concerted actions of cooperative study groups. Remarkably,
the routine assessment of MRD in adult patients with ALL,
who generally have worse prognoses than their pediatric
counterparts, remains uncommon. There are likely many
factors contributing to this current state of the art, not least
of which is the distribution of adult ALL patient care
throughout a large number of institutions with very het-
erogeneous diagnostic capabilities. For many patients,
routine MPFC assessment of MRD is not possible; likewise,
the development of patient-speciﬁc RQ-PCR assays is not
feasible. As a consequence of the disparate infrastructure
capabilities at centers where adult ALL patients receive
treatment, the availability of an assay that does not require
patient-speciﬁc reagents, yet that can be performed on
archived or fresh mononuclear cell isolates, offers the po-
tential for innovation in adult ALL management.
The current RQ-PCR method for MRD quantiﬁcation re-
quires identiﬁcation of clonal rearrangements via heterodu-
plex gel electrophoresis, traditional Sanger sequencing of
each diagnostic clone, and a laborious process of RQ-PCR
primer/probe development and validation for each patient-
speciﬁc assay. When multiple clonotypes at multiple Ig/TCR
genes are present at diagnosis, as is frequently the case in
ALL, developing RQ-PCR assays for each clonotype may be
unfeasible. As an alternative to this resource-intensive
approach, we have developed methods using multiplexed
PCR and massively parallel HTS to identify leukemia-marker
clones and quantify them in post-treatment clinical speci-
mens. Using this approach, clonal immunoreceptor gene
rearrangements may be quantiﬁed in a mixture of polyclonal
B or T cells, enabling highly sensitive MRD quantiﬁcation. We
previously demonstrated methods for quantifying MRD in
CLL using IGH-VDJ clonotypes ampliﬁed by consensus-
primer multiplex PCR followed by IGH HTS and bio-
informatic quantiﬁcation [26-28].
The LymphoSIGHT platform (Sequenta), a robust method
for absolute MRD quantiﬁcation using HTS, has been devel-
oped and provides highly sensitive and speciﬁc MRD quan-
tiﬁcation in lymphoid malignancies [18,27]. The
LymphoSIGHT (Sequenta) platform has also demonstrated
adequate sensitivity for detection of non-Hodgkin lympho-
maeassociated clonotypes in cell-free DNA circulating in the
PB [29]. LymphoSIGHT (Sequenta) uses multiplexed PCR and,
thus, has the beneﬁt of being applicable to all patients
without the reagent customization required for allele-
speciﬁc RQ-PCR techniques. Furthermore, because of the
advantages of scalability and automation of large dataset
analysis, the detection threshold of this method is 106 with
adequately cellular specimens, which cannot easily be ach-
ieved using RQ-PCR or ﬂow cytometry. This additional degree
of sensitivity permits the assessment of PB for MRD, even in
diseases where malignant cells concentrate in the BM.
Whereas most chronic lymphocytic leukemia (CLL) iso-
lates have a stable IGH clonotype exhibiting limited clonal
evolution [26,30], the IGH locus is not clonally rearranged in
up to one half of patients with ALL. The IGH locus may also be
prone to clonal evolution in ALL lymphoblasts by VH segment
replacement, meaning the locus may evolve as the malig-
nancy progresses or relapses after therapy [31-33]. This
phenomenon cannot easily be accounted for by standard RQ-
PCR techniques, as subclones may not be captured by the
heteroduplex gel electrophoresis method and any RQ-PCR
A.C. Logan et al. / Biol Blood Marrow Transplant 20 (2014) 1307e13131312assay will only detect a single clonotype. Using massively
parallel IGH-HTS, it is possible to identify and quantify clo-
notypes that are related by D-N-J sequence identity but differ
in VH segment sequences [33].
From a methodological perspective, ALL presents chal-
lenges to the universal application of Ig/TCR-HTS that are
important to resolve. For one, several studies have reported
that 25% to 50% of B-ALL patients do not have a disease-
associated IGH-VDJ clonotype [19-21]. In addition, as dis-
cussed above, the clonal switch at the IGH locus may limit its
usefulness as a post-therapy disease marker [23,31],
although IGH oligoclonality appears to be less common in
adult patients than in pediatric patients [34]. Fortunately,
other genetic targets for clonotyping ALL exist, which may
overcome the limitations imposed by the lack of stable IGH
clonotypes, including partial IGH-DJ rearrangements, which
likely capture an additional 10% to 30% of patients [20,22,23],
or rearrangements of the IGL or IGK loci, which may be
detectable in up to 50% of patients, in some series [19].
Additionally, TCRB, TCRD, or TCRG loci are rearranged in a
signiﬁcant percentage of both B cell (30% to 50%) and T cell
(up to 75%) ALL isolates [20,24,25]. Performing consensus
PCR at all these loci is feasible, but the routine development
of RQ-PCR assays, given the multitude of possible targets, is
not scalable to widespread use.
In the work presented here, we have demonstrated appli-
cation of the LymphoSIGHT platform (Sequenta) to ALL MRD
quantiﬁcationbefore andafter allo-HCT. The advantages of the
LymphoSIGHTmethod (Sequenta) aremanifold, including the
following: (1) wide access to MRD quantiﬁcation via a central
reference lab (or labs, depending on assay volume within a
region), with standardized processes for sample handling and
clone identiﬁcation; (2) the use of multiplexed PCR to capture
relevant immunoreceptor clonotypes associated with the
leukemic clone to permit the complexity of leukemic oligo-
clonality tobequantiﬁed; and(3) thehighdegreeof sensitivity
that can be achieved, provided a suitable sample with
adequate leukocyte genome input.
Using the LymphoSIGHT platform (Sequenta) for clono-
type identiﬁcation, we identiﬁed Ig/TCR rearrangements
suitable for MRD quantiﬁcation in 93% of patients in this
series. Of the 27 patients with leukemic isolates exhibiting
molecular clonality, over 50% had more than 1 clonal locus
suitable for MRD quantiﬁcation, which correlates well with
other studies using standard techniques for clonality iden-
tiﬁcation [13]. Although LymphoSIGHT (Sequenta) can be
used to address oligoclonality and clonal evolution, we
elected not to address clonal evolution during the treatment
courses of patients in this cohort because, for some cases, the
only sample available for identiﬁcation of leukemia-
associated clonotypes was a relapse sample. Comparison of
Ig/TCR-HTS-quantiﬁed leukemia burdens in PB and BM
revealed the latter to have a median 8.4-fold higher disease
burden. This ﬁnding suggests that the deep sensitivity of the
LymphoSIGHT method (Sequenta) may be useful for quan-
tifying MRD in PB, even when BM disease burden is in the
104 range. This will require additional validation in a larger
cohort of patients, however, and we note that it is sometimes
not possible to achieve 106 sensitivity when fewer than 1
million recoverable cell genomes are present in cytopenic
blood samples at early post-transplantation time points in
some patients.
Pre-HCT MRD quantiﬁcation using Ig/TCR-HTS analysis of
PB or BM samples is predictive of post-HCT relapse when
disease burden before conditioning is 104. Post-HCT MRD106 is highly associated with relapse and poor survival. In
this study, only 5 patients were treated with NMA condi-
tioning; the vast majority received myeloablative condi-
tioning, a setting in which detectable residual disease
burden, even at the 106 level, within the ﬁrst 3 months after
HCT appears to be associated with relapse and extremely
limited salvageability. Although additional study in the NMA
setting will be required, as the kinetics of disease clearance
may differ in comparison with patients undergoing mye-
loablative conditioning, we note that none of the NMA-
conditioned patients in this series who were MRD positive
during the ﬁrst 100 days after HCT subsequently became
MRD negative.
We found that quantiﬁcation of MRD in PB gives a lead
time to clinical relapse of roughly 3 months, which is similar
to the ﬁndings of Uzunel et al. using RQ-PCRebased MRD
quantiﬁcation in BM aspirates after allo-HCT [35]. Thus, the
higher sensitivity of this HTS approach for MRD quantiﬁca-
tion is a clinically useful assay characteristic that enables
assessment of PB samples on a more frequent schedule than
would likely be feasible for most patients if only BM were
assessed. Increasing the frequency of molecular disease
measurement will likely improve the diagnostic lead-time
before clinical relapse and could provide an opportunity to
apply additional therapeutic maneuvers while disease
burden is low. Topp et al. recently demonstrated, for
example, the utility of treating ALL patients withMRD> 104
after induction chemotherapy with an immune targeting
therapy, blinatumomab, which directs T cell eradication of
CD19þ B cells, including ALL lymphoblasts [36,37].
Our study conﬁrms that in the posteallo-HCT setting, ALL
MRD positivity is associated with extremely high risk of
relapse and uniformly poor outcomes. Bone marrow
assessment is not always feasible, and frequent BM aspira-
tion is generally undesirable formost patients, so quantifying
MRD in PB using highly sensitive Ig/TCR-HTS may yield
signiﬁcantly improved feasibility for post-HCT MRD moni-
toring plans. The dismal outcome of patients with ALL who
relapse after allo-HCT demands further clinical study of both
post-transplantation MRD monitoring and novel methods
for treating ALL relapse in evolution.
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